VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 31, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) announces that subject to regulatory approval it will grant additional options in the amount of 50,000 to Brisco Capital Partners Corp. and 50,000 to Graeme Dick pursuant to their IR Consulting Agreement as amended as well as 50,000 to Hamza Thindal Capital Corporation pursuant to their Marketing Consulting Communications Agreement as amended. The options are exercisable for two years at $1.23 per share and each grant is subject to vesting over 12 months as follows: 12,500 three months after date of grant and 12,500 each three months thereafter.
ABOUT BIOASIS:
biOasis Technologies Inc. is a biopharmaceutical company engaged in the development and commercialization of products for the diagnosis and treatment of neurological diseases and disorders.
On Behalf of the Board of Directors
Rob Hutchison Chairman & CEO
"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."
Contact Information:
Rob Hutchison
Chairman & CEO
(778) 383.3280
rob@bioasis.ca
www.bioasis.ca